Interestingly, our data reveal that ZNF217 overexpression also enables ovarian cancer cells to resist extant chemotherapeutics and can thus contribute to the poor clinical outcome (Fig. 7J). This evidence concerns the gene ZNF217 and ovarian carcinoma.